Therefore, therapeutic AChE inhibitors such as donepezil, rivastigmine, and galactamine are developed based on the cholinergic hypothesis and are currently used for AD treatments, which have shown short-term improvements in progressive cognitive decline [11,12]. The gene discussed is ACHE; the disease is Alzheimer disease.